Atyr PHARMA (NASDAQ:ATYR) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $35.00 target price on the stock.

A number of other research firms have also recently weighed in on ATYR. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Atyr PHARMA in a report on Wednesday, August 14th. Wells Fargo & Company began coverage on Atyr PHARMA in a research report on Friday, October 4th. They set an “overweight” rating and a $17.00 target price on the stock. Finally, Jefferies Financial Group started coverage on shares of Atyr PHARMA in a report on Thursday, September 5th. They issued a “buy” rating and a $9.00 price target for the company.

Atyr PHARMA Trading Down 6.5 %

Atyr PHARMA stock opened at $3.33 on Tuesday. The stock has a market cap of $279.52 million, a price-to-earnings ratio of -3.54 and a beta of 1.07. Atyr PHARMA has a 12 month low of $1.14 and a 12 month high of $3.80. The stock has a 50 day moving average of $2.82. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). On average, equities research analysts forecast that Atyr PHARMA will post -0.89 EPS for the current year.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.